Drug-Drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

A Phase 1, Randomized, Double-blind, Placebo-controlled, Sequential-group, Multiple-dose, Drug-drug Interaction Study of VCH-222 and Telaprevir in Healthy Subjects

The purpose of this study is to investigate the pharmacokinetics, safety, and tolerability of the co-administration of VCH-222 and telaprevir in healthy subjects.

Inclusion Criteria:

• Healthy males, and/or healthy females of non-childbearing potential, aged 18 to 55 years (inclusive)
• Body mass index (BMI) between 18 and 31 kg/m2 (inclusive) and weight > 50 kg

Exclusion Criteria:

• Women of child bearing potential
• Subjects positive for Hepatitis B, Hepatitis C, or HIV
• Subjects who have participated in a clinical study involving administration of an investigational drug within 2 months